Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on modulating the gut microbiome to address gastrointestinal diseases. The company was co-founded in 2004 by Andrew J. Ritter and his father, Ira Ritter. The inspiration for the company stemmed from Andrew Ritter's own personal struggles with lactose intolerance, which began in childhood. His early research and self-experimentation as a teenager formed the basis for the company's lead product candidate.

The company's primary business was the development of novel therapeutics. Its lead drug candidate, RP-G28, was a non-digestible oligosaccharide designed to stimulate lactose-metabolizing bacteria in the colon. This mechanism aimed to adapt the gut microbiome, thereby reducing symptoms associated with lactose intolerance such as abdominal pain, bloating, and gas. The intended treatment regimen was a 30-day course, after which patients could potentially tolerate dairy products long-term. Ritter Pharmaceuticals operated in the biotechnology sector, specifically targeting the large market of individuals suffering from lactose intolerance. As a clinical-stage company, its business model was centered on research and development, funded through capital raises. Andrew Ritter led the company through its initial public offering on the NASDAQ (ticker: RTTR), raising significant institutional capital to fund its clinical trials.

A significant milestone for Ritter Pharmaceuticals was advancing RP-G28 into a pivotal Phase 3 clinical trial, named "Liberatus". However, in September 2019, the company announced that the trial failed to meet its primary endpoint, as it did not show a statistically significant difference in symptom reduction compared to a placebo. Following this setback and a review of strategic alternatives, Ritter Pharmaceuticals entered into a definitive reverse merger agreement with Qualigen, Inc. in January 2020. The merger was completed in May 2020, resulting in the formation of a new entity named Qualigen Therapeutics, Inc. (NASDAQ: QLGN). The combined company shifted its focus to Qualigen's pipeline of cancer and infectious disease therapeutics, and Ritter Pharmaceuticals ceased to exist as an operating entity. Its officers, including Andrew and Ira Ritter, resigned from their positions upon the merger's completion, with Ira Ritter taking a seat on the new company's board.

Keywords: Ritter Pharmaceuticals, gut microbiome, lactose intolerance, RP-G28, gastroenterology, clinical trials, Andrew Ritter, Ira Ritter, biopharmaceutical, therapeutic development, colonic adaptation, oligosaccharide, NASDAQ: RTTR, Qualigen Therapeutics, reverse merger, gut health, digestive disorders, clinical-stage biotechnology, Liberatus trial, microbiome modulation